A comparative study of high-dose-rate brachytherapy boost combined with external beam radiation therapy versus external beam radiation therapy alone for high-risk prostate cancer. (5th April 2021)

• Record Type: Journal Article
• Authors: Oshikane, Tomoya; Kaidu, Motoki; Abe, Eisuke; Ohta, Atsushi; Saito, Hirotake; Nakano, Toshimichi; Honda, Moe; Tanabe, Satoshi; Utsunomiya, Satoru; Sasamoto, Ryuta; Ishizaki, Fumio; Kasahara, Takashi; Nishiyama, Tsutomu; Tomita, Yoshihiko; Aoyama, Hidefumi; Ishikawa, Hiroyuki
• Is Part Of: Journal of radiation research. Volume 62:Number 3(2021)
• Page Start: 525
• Page End: 532
• Publication Date: 2021-04-05
• Subjects: high-dose-rate brachytherapy -- intensity-modulated radiation therapy -- prostate cancer -- biochemical-free survival; Radiology, Medical -- Periodicals; Radiobiology -- Periodicals; Radiation -- Periodicals; 616.0757
• DOI: 10.1093/jrr/rrab006
• Languages: English
• ISSNs: 0449-3060

Abstract

Abstract: We aimed to compare the outcomes of high-dose-rate brachytherapy (HDR-BT) boost and external beam radiation therapy (EBRT) alone for high-risk prostate cancer. This was a single-center, retrospective and observational study. Consecutive patients who underwent initial radical treatment by HDR-BT boost or EBRT alone from June 2009 to May 2016 at the Niigata University Medical and Dental Hospital, Japan were included. A total of 96 patients underwent HDR-BT boost, and 61 underwent EBRT alone. The prescription dose of HDR-BT boost was set to 18 Gy twice a day with EBRT 39 Gy/13 fractions. The dose for EBRT alone was mostly 70 Gy/28 fractions. The high-risk group received >6 months of prior androgen deprivation therapy. Overall survival, biochemical-free survival, local control and distant metastasis-free survival rates at 5 years were analyzed. The incidence of urological and gastrointestinal late adverse events of Grade 2 and above was also summarized. In the National Comprehensive Cancer Network (NCCN) high-risk calssification, HDR-BT boost had a significantly higher biochemical-free survival rate at 5 years (98.9% versus 90.7%, P = 0.04). Urethral strictures were more common in the HDR-BT boost group. We will continuously observe the progress of the study patients and determine the longer term results.